Therapeutic equivalence? [Design Issues]

posted by bjkim97  – Korea / Seoul, 2011-03-03 13:37 (5583 d 05:18 ago) – Posting: # 6693
Views: 8,705

Thank you for reply MR Dan

But no one expected the authorities of your country permit did not have?
As you know yourself, FDA recommend that patients with Imatinib to look at is.
Not available as well as healthy adults, but not the PK DATA, Issue, did not we.

Yet I did not proceed too many questions to be asked.
We look forward to in kind. ^_^;;

Thank you so much Dan
BJ


Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
145 visitors (0 registered, 145 guests [including 19 identified bots]).
Forum time: 19:55 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5